Van Lanschot Kempen Investment Management N.V. Has $15.52 Million Position in IQVIA Holdings Inc. (NYSE:IQV)

Van Lanschot Kempen Investment Management N.V. lowered its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 35.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 78,981 shares of the medical research company's stock after selling 44,132 shares during the quarter. Van Lanschot Kempen Investment Management N.V.'s holdings in IQVIA were worth $15,521,000 as of its most recent filing with the SEC.

Other large investors also recently made changes to their positions in the company. Smith Group Asset Management LLC acquired a new position in IQVIA during the 4th quarter worth approximately $1,616,000. Nordea Investment Management AB increased its holdings in IQVIA by 47.4% in the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company's stock valued at $277,908,000 after buying an additional 452,029 shares during the last quarter. Hickory Asset Management Inc. acquired a new stake in shares of IQVIA during the 4th quarter valued at approximately $941,000. Fifth Third Bancorp raised its holdings in shares of IQVIA by 13.0% during the fourth quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company's stock worth $2,590,000 after purchasing an additional 1,521 shares during the period. Finally, Graphene Investments SAS boosted its holdings in shares of IQVIA by 22.0% in the 4th quarter. Graphene Investments SAS now owns 15,000 shares of the medical research company's stock valued at $2,948,000 after buying an additional 2,700 shares during the period. Institutional investors and hedge funds own 89.62% of the company's stock.

IQVIA Stock Down 0.2 %

NYSE IQV traded down $0.30 during trading on Friday, hitting $150.38. The stock had a trading volume of 1,333,062 shares, compared to its average volume of 1,419,099. The company has a market capitalization of $26.51 billion, a PE ratio of 20.05, a P/E/G ratio of 1.99 and a beta of 1.46. IQVIA Holdings Inc. has a 12 month low of $135.97 and a 12 month high of $252.88. The company's 50-day moving average price is $172.46 and its two-hundred day moving average price is $194.57. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84.

IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on IQV. Royal Bank of Canada restated an "outperform" rating and set a $270.00 price objective on shares of IQVIA in a research report on Monday, February 10th. Citigroup cut their price target on shares of IQVIA from $225.00 to $210.00 and set a "neutral" rating for the company in a report on Tuesday, March 4th. JPMorgan Chase & Co. reduced their target price on shares of IQVIA from $240.00 to $232.00 and set an "overweight" rating for the company in a report on Tuesday, February 18th. StockNews.com lowered IQVIA from a "buy" rating to a "hold" rating in a research note on Wednesday, March 12th. Finally, HSBC lowered IQVIA from a "buy" rating to a "hold" rating and cut their target price for the stock from $260.00 to $160.00 in a research report on Friday. Seven equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $237.62.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.